MYC and Miyoshi myopathy: Consistent with synergistic Sp1 reduction by panobinostat and the proteasome inhibitors, bortezomib (Figure 4D) or carfilzomib (Figure 4E) in combination with panobinostat further diminished cMyc and IRF4 levels in MM cells.